Aquabounty has waited years for U.S. Food and Drug Administration approval to sell its genetically modified salmon, which could have a chilling effect on other companies considering biotechnology investments, experts say. The company, which adds a Chinook salmon growth hormone to Atlantic salmon to speed their growth, has almost run out of money waiting for approval. "The story of Aquabounty is disappointing because everyone was hoping the company would be a clear signal that genetic modification in animals is now acceptable in the U.S.," said Helen Sang, a University of Edinburgh geneticist.

Related Summaries